Preis, Lukas
Villringer, Kersten
Brosseron, Frederic
Düzel, Emrah
Jessen, Frank
Petzold, Gabor C.
Ramirez, Alfredo
Spottke, Annika
Fiebach, Jochen B.
Peters, Oliver
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
Article History
Received: 15 June 2024
Accepted: 14 July 2024
First Online: 31 July 2024
Declarations
:
: The research received ethical approval from the Ethics Commission of Charité University Medicine Berlin (Local ethics approval number: EA4/136/19, ClinicalTrials-gov ID: NCT04093882, first submitted 2019-09-13). Each participant provided written consent after being informed.
: All authors consent publication of this article.
: The authors declare no competing interests.
: JBF reports consulting and advisory board fees from AbbVie, AC Immune, Alzheon, Artemida, BioClinica/Clario, Biogen, Bristol Myers Squibb, Brainomix, Cerevast, C2N Diagnostics, Daiichi-Sankyo, EISAI, Eli Lilly, F. Hoffmann-LaRoche AG, GlaxoSmithKline, Guerbet, Ionis Pharmaceuticals, IQVIA, Janssen, Julius Clinical, jung diagnostics, Lantheus Medical Imaging, Merck, Novo Nordisk, Octapharma AG, Premier Research, ProPharma Group, Prothena Biosciences, Regeneron Pharmaceuticals, Roche, Syneos, Tau Rx, Vertex Pharmaceuticals, and Worldwide Clinical Trials outside the submitted work.